PPAR-Gamma Agonist Pioglitazone Reduced CD68+ but Not CD163+ Macrophage Dermal Infiltration in Obese Psoriatic Patients
Background. Macrophages are of great importance in the development of obesity and psoriasis. Signaling via PPAR-γ in certain macrophage populations is associated with M2-like features and anti-inflammatory profile. In this research, we evaluated the anti-inflammatory action of pioglitazone by the im...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-01-01
|
| Series: | PPAR Research |
| Online Access: | http://dx.doi.org/10.1155/2020/4548012 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850217682921586688 |
|---|---|
| author | Ya. O. Yemchenko V. I. Shynkevych K. Ye Ishcheikin I. P. Kaidashev |
| author_facet | Ya. O. Yemchenko V. I. Shynkevych K. Ye Ishcheikin I. P. Kaidashev |
| author_sort | Ya. O. Yemchenko |
| collection | DOAJ |
| description | Background. Macrophages are of great importance in the development of obesity and psoriasis. Signaling via PPAR-γ in certain macrophage populations is associated with M2-like features and anti-inflammatory profile. In this research, we evaluated the anti-inflammatory action of pioglitazone by the immunohistochemical study of M1 and M2 macrophages in psoriasis-affected skin in obese patients. Methods. We used immunohistochemistry to characterize CD68+ and CD163+ macrophages and pathomorphological description of skin biopsy, obtained from 6 obese psoriatic patients before and after treatment with 15, 30, and 45 mg pioglitazone, once a day during 6 months. Two patients with conventional therapy and without pioglitazone served as control. Results. Generally, CD163+ cell quantities in psoriasis-affected skin significantly dominated over CD68+ before and after all treatment regiments. Among patients who received pioglitazone, some of them clearly responded to treatment from lowest to highest doses by decreasing CD68+ cells. In the group with 30 mg pioglitazone regiment, we detected a significant reduction of CD68+ cells in dermal infiltrates: CI 95% (16–32) before versus CI 95% (2–7) after treatment. Pioglitazone dose escalation led to certain normalization of skin morphology. Conclusion. The immunohistochemical study allows us to show the anti-inflammatory effect of pioglitazone in psoriatic obese patients, which can be mediated by reducing the number of СD68+ macrophages, but not СD163+ macrophages, in the affected dermis. |
| format | Article |
| id | doaj-art-3795ed0378644b00bba32619dee09fda |
| institution | OA Journals |
| issn | 1687-4757 1687-4765 |
| language | English |
| publishDate | 2020-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | PPAR Research |
| spelling | doaj-art-3795ed0378644b00bba32619dee09fda2025-08-20T02:07:59ZengWileyPPAR Research1687-47571687-47652020-01-01202010.1155/2020/45480124548012PPAR-Gamma Agonist Pioglitazone Reduced CD68+ but Not CD163+ Macrophage Dermal Infiltration in Obese Psoriatic PatientsYa. O. Yemchenko0V. I. Shynkevych1K. Ye Ishcheikin2I. P. Kaidashev3Ukrainian Medical Stomatological Academy, Poltava 36024, UkraineUkrainian Medical Stomatological Academy, Poltava 36024, UkraineUkrainian Medical Stomatological Academy, Poltava 36024, UkraineUkrainian Medical Stomatological Academy, Poltava 36024, UkraineBackground. Macrophages are of great importance in the development of obesity and psoriasis. Signaling via PPAR-γ in certain macrophage populations is associated with M2-like features and anti-inflammatory profile. In this research, we evaluated the anti-inflammatory action of pioglitazone by the immunohistochemical study of M1 and M2 macrophages in psoriasis-affected skin in obese patients. Methods. We used immunohistochemistry to characterize CD68+ and CD163+ macrophages and pathomorphological description of skin biopsy, obtained from 6 obese psoriatic patients before and after treatment with 15, 30, and 45 mg pioglitazone, once a day during 6 months. Two patients with conventional therapy and without pioglitazone served as control. Results. Generally, CD163+ cell quantities in psoriasis-affected skin significantly dominated over CD68+ before and after all treatment regiments. Among patients who received pioglitazone, some of them clearly responded to treatment from lowest to highest doses by decreasing CD68+ cells. In the group with 30 mg pioglitazone regiment, we detected a significant reduction of CD68+ cells in dermal infiltrates: CI 95% (16–32) before versus CI 95% (2–7) after treatment. Pioglitazone dose escalation led to certain normalization of skin morphology. Conclusion. The immunohistochemical study allows us to show the anti-inflammatory effect of pioglitazone in psoriatic obese patients, which can be mediated by reducing the number of СD68+ macrophages, but not СD163+ macrophages, in the affected dermis.http://dx.doi.org/10.1155/2020/4548012 |
| spellingShingle | Ya. O. Yemchenko V. I. Shynkevych K. Ye Ishcheikin I. P. Kaidashev PPAR-Gamma Agonist Pioglitazone Reduced CD68+ but Not CD163+ Macrophage Dermal Infiltration in Obese Psoriatic Patients PPAR Research |
| title | PPAR-Gamma Agonist Pioglitazone Reduced CD68+ but Not CD163+ Macrophage Dermal Infiltration in Obese Psoriatic Patients |
| title_full | PPAR-Gamma Agonist Pioglitazone Reduced CD68+ but Not CD163+ Macrophage Dermal Infiltration in Obese Psoriatic Patients |
| title_fullStr | PPAR-Gamma Agonist Pioglitazone Reduced CD68+ but Not CD163+ Macrophage Dermal Infiltration in Obese Psoriatic Patients |
| title_full_unstemmed | PPAR-Gamma Agonist Pioglitazone Reduced CD68+ but Not CD163+ Macrophage Dermal Infiltration in Obese Psoriatic Patients |
| title_short | PPAR-Gamma Agonist Pioglitazone Reduced CD68+ but Not CD163+ Macrophage Dermal Infiltration in Obese Psoriatic Patients |
| title_sort | ppar gamma agonist pioglitazone reduced cd68 but not cd163 macrophage dermal infiltration in obese psoriatic patients |
| url | http://dx.doi.org/10.1155/2020/4548012 |
| work_keys_str_mv | AT yaoyemchenko ppargammaagonistpioglitazonereducedcd68butnotcd163macrophagedermalinfiltrationinobesepsoriaticpatients AT vishynkevych ppargammaagonistpioglitazonereducedcd68butnotcd163macrophagedermalinfiltrationinobesepsoriaticpatients AT kyeishcheikin ppargammaagonistpioglitazonereducedcd68butnotcd163macrophagedermalinfiltrationinobesepsoriaticpatients AT ipkaidashev ppargammaagonistpioglitazonereducedcd68butnotcd163macrophagedermalinfiltrationinobesepsoriaticpatients |